Impact of Cloud Encounter Mitigation Procedures on Operational and Economic Effectiveness of HLFC Aircraft

The objective of this paper is to investigate the effect of cloud encounter mitigation procedures on operational and economic effectiveness of aircraft with hybrid laminar flow control (HLFC) based on real-world flight routes and weather data. The objective is to evaluate whether cloud mitigation procedures are an appropriate measure to maximize the expected benefit of HLFC-technology under realistic meteorological boundary conditions. A global analysis of cloud encounter on typical airline routes has been conducted based on atmospheric data provided by the European Centre for Medium-Range Weather Forecasts. Different routing procedures have been benchmarked against each other and the most appropriate procedure for daily flight operation will be discussed. For optimizing the daily route planning of HLFC aircraft with respect to cost (direct routing with cloud Encounter and performance losses vs. re-routed flightpath) models for lateral trajectory optimization and calculation have been applied

Cloud Encounter Impact on Operational and Economical Effectiveness of Hybrid Laminar Flow Control

Hybrid laminar flow control (HLFC) on transport aircraft is one of many promising fuel reduction technologies. However, due to high sensitivities of HLFC toward operational boundary conditions, estimations of its overall benefit are usually afflicted with large uncertainties. Among the critical environmental factors is the degradation of laminarity when flying through clouds at high altitudes. This paper provides an assessment on operational and economical effectiveness of HLFC aircraft with a detailed inclusion of the cloud encounter effect in three steps. First the expected time in cloud (TIC) in a real route network with cloud data given by the European Centre for Medium-Range Weather Forecast is analyzed, yielding an average TIC of 10%. Subsequently, HLFC fuel efficiency with and without considering the cloud effect on mid- to long-range aircraft is dealt with. Results show an average drop of fuel benefit from 12.8 to 12.0% due to clouds. The effectiveness of lateral route optimization to reduce the impact of clouds is investigated in the last analysis. Outcomes show that these mitigation strategies are economically beneficial for few cases only. The overall picture confirms that cloud encounter must not be neglected when assessing aircraft with HLFC

Maggot Therapy and its Implications in Veterinary Medicine: An Overview

Alternative therapies to conventional wound management are available now-a-days to facilitate faster wound healing without any complications. Among various alternative therapies, it has been well established that maggot therapy can be used successfully to treat chronic long-standing infected wounds which previously failed to respond to conventional treatment. Maggot therapy employs the use of freshly emerged, sterile larvae of the common greenbottle fly, Phaenicia (Lucilia) sericata, and is a form of artificially induced myiasis in a controlled clinical situation. Maggot therapy, however, is used relatively little in veterinary medicine. Nevertheless, concern over antibiotic resistance and the increase in demand for organic husbandry and residue-free meat and milk, suggest that it is an option which merits further consideration. In this review article, authors’ discuss the role of maggots and their preparation for veterinary medical use

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer

Immune checkpoint inhibitors have become the standard of care in the treatment of metastatic non-small-cell lung cancer (NSCLC). The combination of nivolumab plus ipilimumab and chemotherapy has been shown to improve outcomes in terms of overall survival (OS) and progression-free survival (PFS). The aim of this study was to evaluate the outcomes of metastatic NSCLC treated in routine practice on the treatment regimen of the CheckMate 9LA protocol. Medical records of 58 patients treated at Soroka and Bnai Zion Medical Centers between May 2020 and February 2022 were analyzed. All patients were treated with a regimen of platinum-based chemotherapy combined with immunotherapy of nivolumab every three weeks and ipilimumab every 6 weeks. The patients received 2–3 cycles of chemotherapy according to the physician’s choice: platinum-based cisplatin or carboplatin with either pemetrexed or paclitaxel. The median PFS was 10.2 months, longer than that of the 9LA trial (6.7 months). Adenocarcinoma patients exhibited a higher median OS of 13.7 (range 5–33) months than squamous cell carcinoma (SCC) patients at 12.3 (5–20) months and PFS of 10.3 (4–33) months, while squamous cell carcinoma patients had a PFS of 9.2 (4–18) months. Patients whose programmed death ligand-1 (PD-L1) tumor expression level was ≥1% showed a higher median OS than those with PD-L1 expression of less than 1%. Treatment-related adverse events (TRAEs) were reported in 93.1% of patients, mostly grade 1 in severity. The first-line treatment of metastatic NSCLC patients in combination with nivolumab plus ipilimumab and chemotherapy can be given safely in routine clinical practice, with results comparable to those achieved in clinical trials of the regimen